Esmeralda Casas-Silva

ORCID: 0000-0002-9704-0812
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Tissue Engineering and Regenerative Medicine
  • Cancer Cells and Metastasis
  • Epigenetics and DNA Methylation
  • Bioinformatics and Genomic Networks
  • Cancer Genomics and Diagnostics
  • Genetics, Bioinformatics, and Biomedical Research
  • Advances in Oncology and Radiotherapy
  • Ethics in Clinical Research
  • Artificial Intelligence in Healthcare
  • Science, Research, and Medicine
  • Economic and Financial Impacts of Cancer
  • Multiple and Secondary Primary Cancers
  • Molecular Biology Techniques and Applications
  • Health Systems, Economic Evaluations, Quality of Life
  • Scientific Computing and Data Management
  • Research Data Management Practices
  • Biomedical Ethics and Regulation
  • Biomedical Text Mining and Ontologies
  • CRISPR and Genetic Engineering
  • Cancer, Hypoxia, and Metabolism
  • RNA modifications and cancer
  • BRCA gene mutations in cancer
  • Radiomics and Machine Learning in Medical Imaging
  • Genomics and Rare Diseases
  • AI in cancer detection

Center for Information Technology
2024

National Cancer Institute
2018-2024

National Institutes of Health
2022

Scripps Research Institute
2016

University of California, San Diego
2011

Rockefeller University
2011

University of Hawaiʻi at Mānoa
2011

University of Hawaii System
2011

Abstract To metastasize, carcinoma cells must attenuate cell–cell adhesion to disseminate into distant organs. A group of transcription factors, including Twist1, Snail1, Snail2, ZEB1, and ZEB2, have been shown induce epithelial mesenchymal transition (EMT), thus promoting tumor dissemination. However, it is unknown whether these factors function independently or coordinately activate the EMT program. Here we report that direct induction Snail2 essential for Twist1 EMT. knockdown completely...

10.1158/0008-5472.can-10-2330 article EN Cancer Research 2011-01-01
Heidi L. Rehm Angela Page Lindsay Smith Jeremy Adams Gil Alterovitz and 95 more Lawrence Babb Maxmillian P. Barkley Michael Baudis Michael J. S. Beauvais Tim Beck J. Beckmann Sergi Beltrán David L. Bernick Alexander Bernier James Bonfield Tiffany Boughtwood Guillaume Bourque Sarion R. Bowers Anthony J. Brookes Michael Brudno Matthew Brush David Bujold Tony Burdett Orion J. Buske Moran N. Cabili Daniel Cameron Robert J. Carroll Esmeralda Casas-Silva Debyani Chakravarty Bimal P. Chaudhari Shu Hui Chen J. Michael Cherry Justina Chung Melissa Cline Hayley Clissold Robert Cook‐Deegan Mélanie Courtot Fiona Cunningham Miro Cupak Robert M. Davies Danielle Denisko Megan Doerr Lena Dolman Edward S. Dove Lewis Jonathan Dursi Stephanie O. M. Dyke James A. Eddy Karen Eilbeck Kyle Ellrott Susan Fairley Khalid A. Fakhro Helen V. Firth Michael S. Fitzsimons Marc Fiume Paul Flicek Ian Fore Mallory Freeberg Robert R. Freimuth Lauren A. Fromont Jonathan Fuerth Clara Gaff Weiniu Gan Elena M. Ghanaim David Glazer Robert C. Green Malachi Griffith Obi L. Griffith Robert L. Grossman Tudor Groza Jaime M. Guidry Auvil Roderic Guigó Dipayan Gupta Melissa Haendel Ada Hamosh David Hansen Reece K. Hart Dean M. Hartley David Haussler Rachele Hendricks‐Sturrup Calvin Wai-Loon Ho Ashley E. Hobb Michael M. Hoffman Oliver Hofmann Petr Holub Jacob Shujui Hsu Jean‐Pierre Hubaux Sarah Hunt Ammar Husami Julius O.B. Jacobsen Saumya S. Jamuar Elizabeth Janes Francis Jeanson Aina Jené Amber L. Johns Yann Joly Steven J.M. Jones Alexander Kanitz Yoshihiro Kato Thomas Keane Kristina Kekesi-Lafrance

The Global Alliance for Genomics and Health (GA4GH) aims to accelerate biomedical advances by enabling the responsible sharing of clinical genomic data through both harmonized aggregation federated approaches. decreasing cost sequencing (along with other genome-wide molecular assays) increasing evidence its utility will soon drive generation sequence from tens millions humans, levels diversity. In this perspective, we present GA4GH strategies addressing major challenges revolution. We...

10.1016/j.xgen.2021.100029 article EN cc-by-nc-nd Cell Genomics 2021-11-01

Abstract Since 2014, the NCI has launched a series of data commons as part Cancer Research Data Commons (CRDC) ecosystem housing genomic, proteomic, imaging, and clinical to support cancer research promote sharing NCI-funded studies. This review describes each (Genomic Commons, Proteomic Integrated Canine Service, Imaging Clinical Translational Commons), including their unique shared features, accomplishments, challenges. Also discussed is how CRDC implement Findable, Accessible,...

10.1158/0008-5472.can-23-2468 article EN cc-by-nc-nd Cancer Research 2024-03-15

Abstract More than ever, scientific progress in cancer research hinges on our ability to combine datasets and extract meaningful interpretations better understand diseases ultimately inform the development of treatments diagnostic tools. To enable successful sharing use big data, NCI developed Cancer Research Data Commons (CRDC), providing access a large, comprehensive, expanding collection data. The CRDC is cloud-based data science infrastructure that eliminates need for researchers...

10.1158/0008-5472.can-23-2730 article EN cc-by-nc-nd Cancer Research 2024-03-15

Proteomics has emerged as a powerful tool for studying cancer biology, developing diagnostics, and therapies. With the continuous improvement widespread availability of high-throughput proteomic technologies, generation large-scale data become more common in research, there is growing need resources that support sharing integration multi-omics datasets. Such datasets require extensive metadata including clinical, biospecimen, experimental workflow annotations are crucial interpretation...

10.1158/2767-9764.crc-24-0243 article EN cc-by Cancer Research Communications 2024-09-01

<div>Abstract<p>Since 2014, the NCI has launched a series of data commons as part Cancer Research Data Commons (CRDC) ecosystem housing genomic, proteomic, imaging, and clinical to support cancer research promote sharing NCI-funded studies. This review describes each (Genomic Commons, Proteomic Integrated Canine Service, Imaging Clinical Translational Commons), including their unique shared features, accomplishments, challenges. Also discussed is how CRDC implement Findable,...

10.1158/0008-5472.c.7213920.v1 preprint EN 2024-05-02

<div>Abstract<p>More than ever, scientific progress in cancer research hinges on our ability to combine datasets and extract meaningful interpretations better understand diseases ultimately inform the development of treatments diagnostic tools. To enable successful sharing use big data, NCI developed Cancer Research Data Commons (CRDC), providing access a large, comprehensive, expanding collection data. The CRDC is cloud-based data science infrastructure that eliminates need for...

10.1158/0008-5472.c.7213802.v1 preprint EN 2024-05-02

<div>Abstract<p>More than ever, scientific progress in cancer research hinges on our ability to combine datasets and extract meaningful interpretations better understand diseases ultimately inform the development of treatments diagnostic tools. To enable successful sharing use big data, NCI developed Cancer Research Data Commons (CRDC), providing access a large, comprehensive, expanding collection data. The CRDC is cloud-based data science infrastructure that eliminates need for...

10.1158/0008-5472.c.7213802 preprint EN 2024-05-02

<div>Abstract<p>Since 2014, the NCI has launched a series of data commons as part Cancer Research Data Commons (CRDC) ecosystem housing genomic, proteomic, imaging, and clinical to support cancer research promote sharing NCI-funded studies. This review describes each (Genomic Commons, Proteomic Integrated Canine Service, Imaging Clinical Translational Commons), including their unique shared features, accomplishments, challenges. Also discussed is how CRDC implement Findable,...

10.1158/0008-5472.c.7213920 preprint EN 2024-05-02
Coming Soon ...